Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study

J. Beier, R. Fuhr, B. Seoane, E. Massana, G. De Miquel, H. Pujol, S. Ruiz (Wiesbaden, Berlin, Germany; Barcelona, Spain)

Source: International Congress 2014 – Asthma and COPD management
Session: Asthma and COPD management
Session type: Thematic Poster Session
Number: 902
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Beier, R. Fuhr, B. Seoane, E. Massana, G. De Miquel, H. Pujol, S. Ruiz (Wiesbaden, Berlin, Germany; Barcelona, Spain). Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study. Eur Respir J 2014; 44: Suppl. 58, 902

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014

Comparison of an innovative multi-dose inhaler with the attributes of an 'ideal' inhaler: A multicentre randomised controlled trial (RCT)
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014


Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014

Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018



Efficacy of the Plasma Cluster® device in mild to moderate asthmatic children: A randomized, double-blind, placebo-controlled, proof-of-concept trial
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013

Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial
Source: International Congress 2016 – Asthma management
Year: 2016


“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial)
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013


Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study
Source: International Congress 2015 – Paediatric asthma and allergy: asthma management
Year: 2015


A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013

INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015

The effect of Theophylline in patients with allergic rhinitis: A double-blind, randomised, crossover study
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014



A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014

Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021


1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014